Nektar Therapeutics [NASDAQ: NKTR] traded at a low on 06/11/20, posting a -7.15 loss after which it closed the day’ session at $20.26. The results of the trading session contributed to over 1260168 shares changing hands. Over the past one week, the price volatility of Nektar Therapeutics stands at 5.20% while the volatility over the past one month is 3.95%.
The market cap for NKTR stock reached $3.74 billion, with 177.19 million shares outstanding and 175.92 million shares in the current float. Compared to the average trading volume of 1.36M shares, NKTR reached a trading volume of 1260168 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.
GET FREE LESSON outside the norm.
What do top market gurus say about Nektar Therapeutics [NKTR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NKTR shares is $31.21 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NKTR stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
CFRA have made an estimate for Nektar Therapeutics shares, keeping their opinion on the stock as Sell, with their previous recommendation back on June 10, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $32 to $26. The new note on the price target was released on May 12, 2020, representing the official price target for Nektar Therapeutics stock. Previously, the target price had yet another raise to $26, while The Benchmark Company analysts kept a Buy rating on NKTR stock. On March 30, 2020, analysts increased their price target for NKTR shares from 18 to 20.
The Average True Range (ATR) for Nektar Therapeutics is set at 1.06, with the Price to Sales ratio for NKTR stock in the period of the last 12 months amounting to 27.30. The Price to Book ratio for the last quarter was 2.77, with the Price to Cash per share for the same quarter was set at 7.29.
How has NKTR stock performed recently?
Nektar Therapeutics [NKTR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.29. With this latest performance, NKTR shares dropped by -6.76% in over the last four-week period, additionally sinking by -9.76% over the last 6 months – not to mention a drop of -39.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NKTR stock in for the last two-week period is set at 40.24, with the RSI for the last a single of trading hit 32.22, and the three-weeks RSI is set at 45.30 for Nektar Therapeutics [NKTR]. The present Moving Average for the last 50 days of trading for this stock 20.46, while it was recorded at 21.82 for the last single week of trading, and 19.94 for the last 200 days.
Nektar Therapeutics [NKTR]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Nektar Therapeutics [NKTR] shares currently have an operating margin of -383.92 and a Gross Margin at +74.25. Nektar Therapeutics’s Net Margin is presently recorded at -384.47.
Return on Total Capital for NKTR is now -22.67, given the latest momentum, and Return on Invested Capital for the company is -24.34. Return on Equity for this stock declined to -28.22, with Return on Assets sitting at -21.35. When it comes to the capital structure of this company, Nektar Therapeutics [NKTR] has a Total Debt to Total Equity ratio set at 32.08. Additionally, NKTR Total Debt to Total Capital is recorded at 24.29, with Total Debt to Total Assets ending up at 22.80. Long-Term Debt to Equity for the company is recorded at 13.50, with the Long-Term Debt to Total Capital now at 10.22.
Reflecting on the efficiency of the workforce at the company, Nektar Therapeutics [NKTR] managed to generate an average of -$609,498 per employee. Receivables Turnover for the company is 2.86 with a Total Asset Turnover recorded at a value of 0.06.Nektar Therapeutics’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 3.80.
Earnings analysis for Nektar Therapeutics [NKTR]
With the latest financial reports released by the company, Nektar Therapeutics posted -0.63/share EPS, while the average EPS was predicted by analysts to be reported at -0.8/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NKTR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nektar Therapeutics go to -7.30%.
Insider trade positions for Nektar Therapeutics [NKTR]
There are presently around $3,875 million, or 99.49% of NKTR stock, in the hands of institutional investors. The top three institutional holders of NKTR stocks are: INVESCO LTD. with ownership of 33,921,398, which is approximately 7.247% of the company’s market cap and around 0.90% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 20,482,919 shares of the stock with an approximate value of $446.94 million in NKTR stocks shares; and FMR LLC, currently with $425.81 million in NKTR stock with ownership of nearly 30.639% of the company’s market capitalization.
Positions in Nektar Therapeutics stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 125 institutional holders increased their position in Nektar Therapeutics [NASDAQ:NKTR] by around 14,418,546 shares. Additionally, 140 investors decreased positions by around 12,026,440 shares, while 43 investors held positions by with 151,135,077 shares. The mentioned changes placed institutional holdings at 177,580,063 shares, according to the latest SEC report filing. NKTR stock had 28 new institutional investments in for a total of 559,162 shares, while 57 institutional investors sold positions of 3,013,967 shares during the same period.